To further validate the anticancer activity of NSLC01 and its correlation with NRF2/NQO1 pathway activation, NSLC01 was tested in a panel of nine low-passage (less than 10 passages) patient-derived pancreatic cancer cell lines established from our PDAC PDXs (Fig. 3A). This evidence concerns the gene NFE2L2 and familial pancreatic carcinoma.